Simon Van Herck
Overview
Explore the profile of Simon Van Herck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
565
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hauck A, Komforth P, Erlenbusch J, Stickdorn J, Radacki K, Braunschweig H, et al.
Biomater Sci
. 2024 Nov;
13(6):1414-1425.
PMID: 39575699
Pharmacokinetics and biodistribution profiles of active substances are crucial aspects for their safe and successful administration. Since many immunogenic compounds do not meet all requirements for safe and effective administration,...
2.
Chen Y, Dombaxe C, DAmato A, Van Herck S, Welch H, Fu Q, et al.
Biomaterials
. 2024 May;
309:122598.
PMID: 38696943
Current vascular grafts, primarily Gore-Tex® and Dacron®, don't integrate with the host and have low patency in small-diameter vessels (<6 mm). Biomaterials that possess appropriate viscoelasticity, compliance, and high biocompatibility...
3.
Guerassimoff L, Ferrere M, Van Herck S, Dehissi S, Nicolas V, De Geest B, et al.
J Control Release
. 2024 Mar;
369:376-393.
PMID: 38554772
Despite their great versatility and ease of functionalization, most polymer-based nanocarriers intended for use in drug delivery often face serious limitations that can prevent their clinical translation, such as uncontrolled...
4.
Zhong Z, Chen Y, Deswarte K, Lauwers H, De Lombaerde E, Cui X, et al.
Adv Healthc Mater
. 2023 Sep;
12(32):e2301687.
PMID: 37772637
Pharmacological strategies to activate innate immune cells are of great relevance in the context of vaccine design and anticancer immune therapy, to mount broad immune responses able to clear infection...
5.
Braet H, Fransen P, Chen Y, Van Herck S, Marien R, Vanhoorne V, et al.
J Control Release
. 2023 Aug;
362:138-150.
PMID: 37619864
Postoperative peritoneal adhesions occur in the majority of patients undergoing intra-abdominal surgery and are one of the leading causes of hospital re-admission. There is an unmet clinical need for effective...
6.
Liu Y, Li H, Zhao H, Hao Y, Van Herck S, Xu Z, et al.
Adv Healthc Mater
. 2022 Mar;
11(12):e2102781.
PMID: 35285581
In situ anti-tumor vaccination is an attractive type of cancer immunotherapy which relies on the effectiveness of dendritic cells (DCs) to engulf tumor antigens, become activated, and present antigens to...
7.
Van Herck S, Feng B, Tang L
Adv Drug Deliv Rev
. 2021 Nov;
179:114020.
PMID: 34756942
Adjuvant is an essential component in subunit vaccines. Many agonists of pathogen recognition receptors have been developed as potent adjuvants to optimize the immunogenicity and efficacy of vaccines. Recently discovered...
8.
Zhao Y, Xie Y, Van Herck S, Nassiri S, Gao M, Guo Y, et al.
Sci Adv
. 2021 Sep;
7(37):eabg7291.
PMID: 34516776
Immune stimulatory antibodies and cytokines elicit potent antitumor immunity. However, the dose-limiting systemic toxicity greatly hinders their clinical applications. Here, we demonstrate a chemical approach, termed “switchable” immune modulator (Sw-IM),...
9.
Jangra S, De Vrieze J, Choi A, Rathnasinghe R, Laghlali G, Uvyn A, et al.
Angew Chem Int Ed Engl
. 2021 Jul;
60(31):16741-16742.
PMID: 34278670
No abstract available.
10.
Lysebetten D, Malfanti A, Deswarte K, Koynov K, Golba B, Ye T, et al.
ACS Appl Mater Interfaces
. 2021 Jan;
13(5):6011-6022.
PMID: 33507728
Peptide-based subunit vaccines are attractive in view of personalized cancer vaccination with neo-antigens, as well as for the design of the newest generation of vaccines against infectious diseases. Key to...